This study involves testing a new treatment combination for patients 75 years or older with a type of blood cancer called diffuse large B cell lymphoma (DLBCL). The study compares the effects of adding a drug called **oral azacitidine** (CC-486) to a standard treatment called R-miniCHOP. R-miniCHOP includes several drugs like rituximab, which helps the body’s immune system attack cancer cells, and prednisone, an anti-inflammatory drug. The goal is to see if the new combination treatment can improve patient outcomes such as shrinking the cancer or extending life without the cancer returning. The trial also evaluates the safety of this combination.
- The study lasts until 5 years after treatment begins, with regular follow-ups.
- Patients will need to visit the hospital for treatment and blood tests.
- Participants may experience side effects like any standard cancer treatments.
How understandable was the trial content above?
Hard to understand
Easy to understand